NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Immune Pharmaceuticals (IMNP) (Immune) announced today that it will hold an Immuno-Oncology R&D Update for investors on December 8, 2016 in New York City. Immune management and several Oncology Key Opinion leaders will review development plans and milestones for Ceplene® and other pipeline assets to be funded separately in the recently announced Immune subsidiary, Cytovia Oncology.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.